The U.S. health officials have recommended a pause in the use of French biotech Valneva’s (NASDAQ:VALN) chikungunya vaccine Ixchiq for those aged 60 years and older amid an ongoing safety review ...

IXCHIQ ® is the world’s first licensed chikungunya vaccine available to address this significant unmet medical need. In addition to Brazil, IXCHIQ ® is approved for the prevention of disease ...

EMA has maintained current recommendations for IXCHIQ ® for people from 12 to 64 years of age. The decision was taken following a plenary meeting of the Pharmacovigilance Risk Assessment ...

With this extension, IXCHIQ ® , the first vaccine against ... signed in 2021 with Instituto Butantan in Brazil for the development, manufacturing and marketing of a local chikungunya vaccine ...

This submission follows the recent positive opinion of the European Medicines Agency (EMA) on extension of IXCHIQ ® label ... Butantan in Brazil for the development, manufacturing and marketing ...

IXCHIQ ® is the world’s first licensed chikungunya ... This includes the only Lyme disease vaccine candidate in advanced clinical development, which is partnered with Pfizer, the world ...